Acción BHC BAUSCH HEALTH COMPANIES INC.
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas Bausch Health Companies Inc. Toronto S.E.

Acciones

BHC

CA0717341071

Mercado cerrado - Toronto S.E.
Otros sitios de cotización
 22:00:00 03/05/2024 		Varia. Cinco días. Varia. 1 de enero.
10,68 CAD -3,35 % Gráfico intradía de Bausch Health Companies Inc. -10,40 % +0,47 %
03/05 RBC rebaja el objetivo de Bausch Health a 10 dólares y mantiene "Perform" sectorial MT
02/05 Las acciones de Bausch Health caen tras los resultados del 1T MT

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
RBC Lowers Bausch Health Target to US$10, Maintains Sector Perform
Bausch Health Announces First Quarter 2024 Results
Bausch Health Shares Fall Following Q1 Results
Bausch Health Q1 Net Loss Narrows on Higher Revenue, Confirms 2024 Revenue Guidance
Bausch: Q1 Earnings Snapshot
Bausch Health Brief: Reaffirmed full-year Revenue and Adjusted EBITDA (non-GAAP) guidance
Bausch Health Brief: Q1 revenues of US$2.15 billion, up 11% on a Reported and 8% on an Organic basis
Bausch Health Companies Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
North American Morning Briefing : Stock Futures -2-
Needham Says Bausch + Lomb's Q1 Showed a "Strong Start" to The Year
Bausch + Lomb Brief: Raising Full-Year 2024 Constant Currency Revenue Growth Guidance
Bausch + Lomb Brief: Q1 Adjusted EBITDA (non-GAAP) of US$180 Million
Bausch + Lomb Brief: Q1 Revenue of US$1.099 Billion; GAAP Net Loss Attributable of $167 Million
Bausch + Lomb Reports "Statistically Significant" Results From Study of Nutritional Supplement for Dry Eyes
Bausch + Lomb Brief: Announcing "Statistically Significant" Results From a Clinical Study of a Novel Daily Nutritional Supplement for Dry Eyes
Bausch Health in 'Stronger Position' for Bausch + Lomb Distribution, RBC Says
RBC Previews Bausch Health's Q1, Trims Target to US$11
RBC Cuts Bausch + Lomb Target to US$18, Reiterates Outperform, as Previews Q1
Bausch Health's Issuer Credit Rating Upgraded by S&P
Bausch Health Gets 'Positive' Court Ruling on Xifaxan With Market Odds of Bausch + Lomb Distribution at 32%, RBC Says
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción BHC
  4. Acción BHC
  5. Noticias Bausch Health Companies Inc.
  6. Otros idiomas